FDA accepts Eisai’s BLA for LEQEMBI subcutaneous autoinjector for alzheimer’s disease treatment EP News Bureau Jan 15, 2025 LEQEMBI’s subcutaneous formulation could simplify maintenance therapy for Alzheimer’s patients, offering a 15-second at-home…
